DRG becomes Clarivate
One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in...
In DRG Blog / Mar, 2021
Formerly known as AMR, our Inpatient Drug Tracking provides a comprehensive analysis and tracking solution.
For pharma companies, there is a major challenge to quantify the quality outcomes of drugs. For many providers, there are new quality measures that will require tracking. Our platforms provide a comprehensive analysis and tracking solution for both.
Drug Tracking in the United States and Europe
Our databases offer comprehensive and detailed audits of inpatient clinical usage for the most commercially relevant therapies.
Our inpatient drug tracking in the United States and Europe allows users to fully understand market shares and customer practice patterns with timely and detailed data that goes beyond sales. Track performance against competitors via global market size and growth analyses, and detect utilization shifts with deep analysis of clinical procedures and trends.
Download our brochures to learn more about the breadth of coverage
China Rx Database
Gain the in-depth data and analytics you need for success in this lucrative Chinese pharmaceutical market with the China Rx Database. Dive deeply into current and emerging treatment patterns, pricing and reimbursement, and physician sentiment. Review drug sale roll-ups across major therapeutic areas. China Rx answers crucial market outlook and brand performance questions.
|
|
One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in...
In DRG Blog / Mar, 2021
Digital pharmacies, which provide a faster and easier way to get prescriptions, are implementing new technologies to improve...
In DRG Blog / Feb, 2021
In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them...
In DRG Blog / Feb, 2021
The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 marked...
In DRG Blog / Feb, 2021